It has been proposed that immunostaining with PC1O, a monoclonal antibody against proliferating cell nuclear antigen (PCNA), is of prognostic value in gastric carcinoma. Gastric carcinomas from a series of 90 patients in whom survival data were known have been studied. There was no relation between the degree of PClO immunostaining assessed semiquantitatively and survival. (3 Clin Pathol 1994;47:473-474) The monoclonal antibody PC 10 recognises proliferating cell nuclear antigen (PCNA) (M 820, Dako), an antibody against glycophorin C, as a negative control. The sections were visualised with diaminobenzidine and counterstained with haematoxylin. The stained sections were assessed independently by three observers (DCM, KMN, and DCR). The semiquantitative grading system that had been found to be the most discriminative in a previous study into gastric carcinoma was used.6 Based on an examination of the whole section a subjective assessment of the proportion of tumour cell nuclei that showed definite immunopositivity was made. 
The consensus between the three observers for the PCNA grade was 88% (K = 0-81). Specimens for which there was disagreement were reassessed and all assigned to the grade chosen by the majority of observers. Thirty seven of the tumours were categorised in the less than 50% grade and 53 tumours as having greater than 50% of tumour cells positive. There was no significant difference between the survival curves for these two groups (figure) . When the tumours were graded into four categories, corresponding to 1-25%, 26-50%, 51-75% and 76-100% of tumour cells positive with PC 10, all four survival curves overlapped. Thus it is considered unlikely that any relation between PC 10 staining and survival would be found in this series if the division between high and low grades were set at a different level. Observer agreement by the four grade system was poor, however, (K = 0 49). There was no relation between PC10 grade and sex, age, histological type (Lauren), tumour stage, or lymph node state.
Discussion
The results of this study do not support the suggestion that PC10 grading has prognostic value in gastric carcinoma. This contrasts with the previous studies,69 and may be due to differences between the groups. The five year survival of the patients in both the previous studies was much better than in the present series, which showed a survival pattern more typical of gastric carcinoma. This is despite the fact that Jain et a16 studied only advanced gastric cancers. In the present study more tumours had high PC10 grades than was described by the other two papers, which may also reflect a difference between the groups of cases. This is more likely, however, to be a reflection of the difficulties encountered in standardising PC10 immunostaining. In particular, the type and duration of tissue fixation, preparation of sections, and differences in the immunostaining protocols can have a large effect upon the proportion of cells that are labelled with this antibody.2410 Also, there are problems associated with the pronounced heterogeneity within these tumours, such that any one tumour block may not be representative. In this study the subjective grading of the tumours was difficult and reproducibility between observers was imperfect.
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